The stock of Centessa Pharmaceuticals plc ADR (CNTA) has gone down by -3.07% for the week, with a -9.49% drop in the past month and a -6.94% drop in the past quarter. The volatility ratio for the week is 5.97%, and the volatility levels for the past 30 days are 7.14% for CNTA. The simple moving average for the past 20 days is -7.79% for CNTA’s stock, with a 16.83% simple moving average for the past 200 days.
Is It Worth Investing in Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Right Now?
Moreover, the 36-month beta value for CNTA is 1.54. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNTA is 90.14M and currently, short sellers hold a 4.03% of that float. On January 20, 2025, CNTA’s average trading volume was 552.97K shares.
CNTA) stock’s latest price update
The stock of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) has increased by 1.95 when compared to last closing price of 14.87. Despite this, the company has experienced a -3.07% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-08 that BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.
Analysts’ Opinion of CNTA
Morgan Stanley, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $26, previously predicting the price at $11. The rating they have provided for CNTA stocks is “Overweight” according to the report published on September 20th, 2024.
B. Riley Securities gave a rating of “Buy” to CNTA, setting the target price at $33 in the report published on September 19th of the previous year.
CNTA Trading at -9.87% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.08% of loss for the given period.
Volatility was left at 7.14%, however, over the last 30 days, the volatility rate increased by 5.97%, as shares sank -13.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.59% lower at present.
During the last 5 trading sessions, CNTA fell by -3.07%, which changed the moving average for the period of 200-days by +33.80% in comparison to the 20-day moving average, which settled at $16.44. In addition, Centessa Pharmaceuticals plc ADR saw -9.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from HUSSAIN IQBAL J, who sale 6,000 shares at the price of $15.29 back on Jan 15 ’25. After this action, HUSSAIN IQBAL J now owns 118,265 shares of Centessa Pharmaceuticals plc ADR, valued at $91,740 using the latest closing price.
HUSSAIN IQBAL J, the Officer of Centessa Pharmaceuticals plc ADR, proposed sale 6,000 shares at $15.12 during a trade that took place back on Jan 15 ’25, which means that HUSSAIN IQBAL J is holding shares at $90,720 based on the most recent closing price.
Stock Fundamentals for CNTA
Current profitability levels for the company are sitting at:
- -23.43 for the present operating margin
- 0.9 for the gross margin
The net margin for Centessa Pharmaceuticals plc ADR stands at -23.37. The total capital return value is set at -0.28. Equity return is now at value -42.73, with -32.83 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -1.54. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -15.91.
Currently, EBITDA for the company is -166.07 million with net debt to EBITDA at 2.1. When we switch over and look at the enterprise to sales, we see a ratio of 243.85. The receivables turnover for the company is 0.17for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.52.
Conclusion
To wrap up, the performance of Centessa Pharmaceuticals plc ADR (CNTA) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
